MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- GSK PHARMA (pharmaceuticals)
- Latest 8 Quarter Result
GSK PHARMA Quarterly Results (GLXO)
Here are the latest quarterly results of GSK PHARMA. For more details, see the GSK PHARMA financial fact sheet and GSK PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
GSK PHARMA Quarterly Results
| No. of Mths Qtr. Ending |
3
Dec-19* |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
3
Mar-21* |
3
Jun-21* |
3
Sep-21* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 7,786 | 7,758 | 6,486 | 8,793 | 8,572 | 8,138 | 7,900 | 10,099 | |
| Other income | Rs m | 165 | 158 | 579 | 90 | 140 | 296 | 317 | 150 | |
| Turnover | Rs m | 7,951 | 7,916 | 7,065 | 8,884 | 8,712 | 8,434 | 8,217 | 10,248 | |
| Expenses | Rs m | 6,542 | 6,022 | 5,345 | 6,745 | 6,517 | 6,429 | 6,383 | 7,334 | |
| Gross profit | Rs m | -6,295 | 1,848 | 1,141 | 1,407 | 2,160 | 519 | 1,517 | 2,765 | |
| Depreciation | Rs m | 183 | 226 | 218 | 220 | 177 | 179 | 177 | 176 | |
| Interest | Rs m | 30 | 15 | 11 | 9 | 9 | 6 | 8 | 4 | |
| Profit before tax | Rs m | -6,343 | 1,766 | 1,491 | 1,269 | 2,114 | 630 | 1,649 | 2,735 | |
| Tax | Rs m | 268 | 385 | 383 | 505 | 549 | 487 | 438 | 693 | |
| Profit after tax | Rs m | -6,612 | 1,381 | 1,108 | 765 | 1,565 | 143 | 1,211 | 2,042 | |
| Gross profit margin | % | -80.9 | 23.8 | 17.6 | 16.0 | 25.2 | 6.4 | 19.2 | 27.4 | |
| Effective tax rate | % | -4.2 | 21.8 | 25.7 | 39.8 | 26.0 | 77.3 | 26.6 | 25.3 | |
| Net profit margin | % | -84.9 | 17.8 | 17.1 | 8.7 | 18.3 | 1.8 | 15.3 | 20.2 | |
| Diluted EPS | Rs | -39.0 | 8.2 | 6.5 | 4.5 | 9.2 | 0.8 | 7.1 | 12.1 | |
| Diluted EPS (TTM) | Rs | 4.7 | 5.5 | 5.3 | -19.8 | 28.4 | 21.1 | 21.7 | 29.3 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: GSK PHARMA 3QFY21 Result Performance Review
More Pharmaceuticals Company Quarterly Results: SUN PHARMA AUROBINDO PHARMA CIPLA DR. REDDYS LAB PIRAMAL ENTERPRISES
Compare GSK PHARMA With: SUN PHARMA AUROBINDO PHARMA CIPLA DR. REDDYS LAB PIRAMAL ENTERPRISES
Today's Market
Sensex Sheds 427 Points, Nifty Ends Near 17,600; Bajaj Finserv, Tata Steel & Tech Mahindra Top Losers(Closing)
Indian share markets witnessed negative trading activity throughout the day today and ended on a weak note.
Views on news
GSK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)
Oct 26, 2021 | Updated on Oct 26, 2021Here's an analysis of the annual report of GSK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)
Feb 10, 2021 | Updated on Feb 10, 2021For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)
Dec 16, 2021In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.
5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)
Dec 3, 2021As the new variant of Covid-19 emerges, keep an eye on these stocks.
This Stock Just Made a Historical Debut on the Exchanges (Views On News)
Nov 15, 2021Shares of the company listed at premium of 253% from its IPO price, the highest ever.
More Views on NewsMost Popular
10 Indian Companies with the Fastest Growth in Dividend Payouts... (Views On News)
Jan 10, 2022These companies have been consistently paying higher dividends for several years.
Tata Steel vs SAIL: Which Stock is Better? (Views On News)
Jan 13, 2022With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.
Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain (Views On News)
Jan 11, 2022The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.
Tech Mahindra's CTC Acquisition: Too Expensive? (Views On News)
Jan 18, 2022Tech Mahindra's acquisition of European IT-company fails to excite investors.
Time to Buy Energy Stocks (Fast Profits Daily)
Jan 14, 2022Energy is a sector that looks set to take off. It's time to get in.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2022
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: How to Profit from Sensex 100,000
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
GSK PHARMA SHARE PRICE
Jan 21, 2022 (Close)
TRACK GSK PHARMA
- Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GSK PHARMA
GSK PHARMA 5-YR ANALYSIS
COMPARE GSK PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
FOLLOW
APP
EQUITYMASTER SUPPORTS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.